Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

3 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 4
3(37.5%)
N/A
3(37.5%)
Phase 2
1(12.5%)
Phase 1
1(12.5%)
8Total
Phase 4(3)
N/A(3)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT06248554Not ApplicableRecruiting

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Role: lead

NCT06248528Not ApplicableActive Not Recruiting

Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

Role: lead

NCT06420440Phase 2Recruiting

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Role: lead

NCT06863389Completed

Comparison of Chen's U-suture Technique with Duct-to-Mucosa Anastomosis and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy

Role: lead

NCT06776185Completed

Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma

Role: lead

NCT06461936Active Not Recruiting

Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC

Role: lead

NCT06463444Phase 1Recruiting

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Role: lead

NCT06311929Phase 4Recruiting

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Role: lead

NCT06311942Phase 4Recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Role: lead

NCT06311916Phase 4Not Yet Recruiting

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

Role: lead

NCT06253364Completed

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Role: lead

NCT06298123Completed

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Role: lead

NCT06102278Completed

ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma Rupture

Role: lead

NCT05307926Completed

Postoperative Adjuvant Therapy of HCC Based on PD-1

Role: lead

NCT05117047Completed

A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular Carcinoma

Role: lead

NCT04076631Unknown

Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma

Role: lead

NCT03767959Not ApplicableUnknown

Chen's U-Suture Technique for Pancreaticojejunostomy Following Pancreaticoduodenectomy

Role: lead

All 17 trials loaded